Audrey Lehmann

TL;DR: A multitude of indirect measures of adherence exist in the literature, however, there is no “gold” standard for measuring adherence to medications and future research and practice interventions should use an internationally accepted, operational standardized definition of medication adherence.

TL;DR: Negative beliefs toward medications were shown to be an independent risk factor of poor adherence and the BMQ could be an effective, easy to implement tool, for use in everyday practice, to identify patients needing interventions to improve adherence to IS.

TL;DR: Adherence is related to the patient’s satisfaction with medication whether assessed with the TSQM® vII or the SatMed-Q®, therefore, these simple questionnaires could be used as predictive tools to identify patients whos’ adherence needs to be improved.

TL;DR: Five predictive factors of this SD were identified, which should be assessed in routine with patients with CIRD receiving biologic treatment: pain, treatment history, self-administration of injections, negative beliefs about treatment, and a lack of perceived medical and social support.

TL;DR: The phase I NANO-RAD trial assessed the safety and maximum tolerated dose of systemic administration of a novel gadolinium-based nanoparticle, AGuIX, in combination with whole brain radiotherapy in patients with multiple brain metastases not suitable for stereotactic radiotherapy as mentioned in this paper.